CNTA

Centessa Pharmaceuticals
CNTA

39.59 USD
+0.02
0.05%
At close Updated Apr 14, 4:00 PM EDT
1 day
0.05%
5 days
-0.15%
1 month
39.94%
3 months
79.22%
6 months
76.66%
Year to date
67.12%
1 year
231.57%
5 years
82.02%
10 years
82.02%
 

About: Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Employees: 118

Healthcare Biotechnology
0
Funds holding %
of 8,116 funds
Explore Fund Trends
0
Analysts bullish %
of 2 analysts
See Analyst Outlook
0
Positive news %
of 16 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™